Axatilimab, a humanized antibody against macrophage colony-stimulating factor receptor (CSF-1R), is in an active phase II clinical trial to dampen pulmonary fibrosis in cGVHD [12]. This evidence concerns the gene CSF1R and pulmonary fibrosis.